Table 3.
RVNA GMCs (with 95% CIs and RVNA concentration ranges), by timepoint and by site (per-protocol cohort).
| PCECV-I499 |
PCECV-I501 |
PCECV-I509 |
PCECV-G |
|||||
|---|---|---|---|---|---|---|---|---|
| Site 1 (N = 28) | Site 2 (N = 40) | Site 1 (N = 33) | Site 2 (N = 43) | Site 1 (N = 30) | Site 2 (N = 40) | Site 1 (N = 30) | Site 2 (N = 41) | |
| Day 14 | ||||||||
| GMC (95% CI) | 19 (10–36) | 56 (34–93) | 16 (9–28) | 44 (27–71) | 9 (5–16) | 64 (39–106) | 20 (10–37) | 54 (33–88) |
| range | 0.6–450 | 0.4–1510 | 0.1–301 | 1.6–1510 | 0.025–61 | 0.7–1510 | 0.2–675 | 2.8–1510 |
| Day 30 | ||||||||
| GMC (95% CI) | 20 (11–36) | 28 (18–44) | 21 (12–37) | 28 (19–43) | 11 (6–19) | 32 (20–49) | 22 (13–39) | 30 (19–46) |
| range | 0.7–301 | 2.4–301 | 0.2–236 | 2.7–1510 | 0.025–83 | 0.4–1510 | 2.4–1094 | 2.4–301 |
| Day 90 | ||||||||
| GMC (95% CI) | 9.2 (6.0–14.0) | 8.6 (4.9–15.0) | 7.7 (5.2–11.0) | 5.7 (3.4–9.6) | 6.3 (4.2–9.4) | 13.0 (7.2–22.0) | 7.5 (5.0–11.0) | 8.4 (4.8–15.0) |
| Range | 2.0–61 | 0.025–301 | 1.7–59 | 0.1–301 | 0.5–59 | 0.5–201 | 0.5–59 | 0.025–301 |
RVNA, rabies virus neutralizing antibody; GMC, geometric mean concentration (expressed in International Units/mL); CI, confidence interval; N, number of study participants in each group; D, day; range, minimum and maximum values for RVNA concentrations.